Heartland Bank & Trust Co Has $901,000 Holdings in Danaher Co. (NYSE:DHR)

Heartland Bank & Trust Co decreased its position in shares of Danaher Co. (NYSE:DHR) by 2.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 3,239 shares of the conglomerate’s stock after selling 83 shares during the period. Heartland Bank & Trust Co’s holdings in Danaher were worth $901,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of DHR. Tsfg LLC grew its holdings in shares of Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the last quarter. nVerses Capital LLC acquired a new position in shares of Danaher during the second quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher during the second quarter valued at approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher in the first quarter valued at approximately $30,000. Finally, MFA Wealth Advisors LLC bought a new position in Danaher in the 2nd quarter worth approximately $51,000. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. UBS Group lowered their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday. TD Cowen boosted their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday. KeyCorp lifted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday. Barclays lowered their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday. Finally, Stephens restated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research report on Wednesday. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average price target of $287.28.

Danaher Stock Performance

Shares of Danaher stock opened at $256.00 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a market cap of $189.62 billion, a price-to-earnings ratio of 43.39, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The stock’s 50-day moving average is $270.43 and its 200-day moving average is $260.43.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Equities analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Danaher news, Director Linda Filler sold 3,928 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the transaction, the director now directly owns 41,149 shares of the company’s stock, valued at $11,501,145.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,059 shares of company stock valued at $8,400,897 in the last 90 days. 11.10% of the stock is currently owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.